<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464461</url>
  </required_header>
  <id_info>
    <org_study_id>2010856</org_study_id>
    <nct_id>NCT03464461</nct_id>
  </id_info>
  <brief_title>Dosing of Ketorolac in the Emergency Department</brief_title>
  <official_title>Dosing of Ketorolac for Four Classes of Complaints in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal dose of ketorolac in the Emergency Department setting is no clear. We will
      compare 3 doses to determine the optimal dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients from 4 groups will be treated with 3 different doses of ketorolac. The groups are 1.
      headache 2. abdominal pain 3. musculo-skeletal pain 4. viral syndrome. The doses will be 0,
      10, 30mgs of ketorolac to clarify the placebo effect and the optimal dosage as a function of
      condition.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 groups with 3 different treatments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>blinded drug</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>pain</measure>
    <time_frame>30 minutes</time_frame>
    <description>pain score on 0-10 scale</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>0 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mg ketorolac - placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg ketorolac - low dose ketorolac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg ketorolac - usual dose ketorolac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>IV drug</description>
    <arm_group_label>0 mg</arm_group_label>
    <arm_group_label>10 mg</arm_group_label>
    <arm_group_label>30 mg</arm_group_label>
    <other_name>Use of placebo, low, usual dose ketorolac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        &gt; 18 y/o

        Exclusion Criteria:

        pregnant allergic other contraindication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Yanos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Yanos, MD</last_name>
    <phone>5738824141</phone>
    <email>yanos@missouri.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Robinson, MD</last_name>
    <phone>5738824141</phone>
    <email>robinsonm@missouri.edu</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>John Yanos</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

